Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Janssen Submits Application for DARZALEX® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval...

JNJ : 138.69 (+1.52%)
Third Pole Therapeutics Announces Inhaled Nitric Oxide Strategic Collaboration with Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson

Third Pole Therapeutics, a privately held company developing and delivering transformative cardio-pulmonary therapies, announced today that it has entered into a strategic collaboration to work with Actelion...

JNJ : 138.69 (+1.52%)
Fifth Annual Fortune 500 Employment Brand Report Published by WilsonHCG

WilsonHCG, a multi-award-winning global talent solutions provider, released its fifth annual Fortune 500 Employment Brand Report.

JNJ : 138.69 (+1.52%)
Johnson & Johnson Vision's Investigational Antihistamine-Releasing Contact Lens Demonstrates Positive Phase 3 Results

Johnson & Johnson Vision today announced that results from two Phase 3 clinical studies evaluating the company's investigational antihistamine-releasing contact lens (etafilcon A with 0.019 mg ketotifen)...

JNJ : 138.69 (+1.52%)
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $136.61, marking a -0.22% move from the previous day.

JNJ : 138.69 (+1.52%)
Markets Right Now: Stock indexes end an indecisive day mixed

NEW YORK (AP) — The latest on developments in financial markets (all times local):

T : 31.29 (+1.69%)
UNP : 161.59 (+0.06%)
JNJ : 138.69 (+1.52%)
M : 24.26 (+1.68%)
VIA : 33.87 (+3.58%)
Settlement Reached Resolving Xarelto Multidistrict Litigation Claims

The makers of the popular blood thinner Xarelto® have reached a $775 million settlement to resolve litigation filed by patients who suffered a bleeding injury after taking the prescription drug.

BAYRY : 16.0950 (-0.53%)
JNJ : 138.69 (+1.52%)
J&J Files Application for Darzalex Label Expansion in Europe

J&J (JNJ) seeks an approval for Darzalex combo pertaining to the newly diagnosed, transplant-ineligible multiple myeloma patient population in the EU.

CELG : 89.50 (+1.80%)
JNJ : 138.69 (+1.52%)
RHHBY : 34.2700 (+1.30%)
BMY : 48.14 (+1.37%)
S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion

S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q4 2018 S&P 500® stock buybacks, or share repurchases, set a fourth consecutive record of $223.0 billion. This displaces the previous...

GOOGL : 1,197.00 (-0.03%)
AAPL : 191.34 (+1.38%)
AVGO : 298.40 (+2.14%)
CSCO : 53.23 (+0.95%)
C : 61.27 (+1.56%)
BAC : 27.15 (+1.15%)
JPM : 99.61 (+0.69%)
JNJ : 138.69 (+1.52%)
MRK : 83.29 (+1.14%)
ORCL : 53.31 (+1.08%)
AMGN : 189.33 (+1.47%)
PFE : 42.46 (+1.36%)
MSFT : 117.98 (+0.27%)
SBUX : 72.97 (+0.93%)
IBM : 140.52 (+0.96%)
WFC : 48.78 (+1.46%)
V : 154.73 (+1.11%)
SPGI : 205.60 (+0.29%)
FB : 168.44 (+1.29%)
HD : 191.39 (+0.90%)
WMT : 98.64 (+0.48%)
Watch for Shares of Johnson&Johnson (JNJ) to Approach Support at $135.86

Shares of Johnson&Johnson (NYSE:JNJ) opened today below their pivot of $137.39 and have already reached the first level of support at $136.38. Should the shares continue to fall, the support pivots of...

JNJ : 138.69 (+1.52%)
Pepperdine Graziadio Business School Announces 50th Anniversary Event That Will Explore the Future of Work

In honor of Pepperdine University Graziadio Business School's 50th anniversary, the school announced today that it will be holding an all-day event on April 2, 2019, at The Novo at...

JNJ : 138.69 (+1.52%)
Ethicon Launches Global Registry To Collect Real-World Data On Liver Lesions Ablated With The NEUWAVE Microwave Ablation System

Johnson & Johnson Medical Devices Companies* today announced Ethicon** has launched a new global registry to collect and analyze real-world data on patients with soft tissue liver lesions ablated with...

JNJ : 138.69 (+1.52%)
Eli Lilly & Co has the Best Relative Performance in the Pharmaceuticals Industry (LLY , MRK , JNJ , PBH , PFE )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

JNJ : 138.69 (+1.52%)
MRK : 83.29 (+1.14%)
LLY : 131.45 (+1.22%)
Janssen Seeks Expanded Use of DARZALEX(R) (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for DARZALEX(R) (daratumumab)...

JNJ : 138.69 (+1.52%)
Cooper Companies' (COO) CooperVision Gains Momentum Globally

Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.

EYE : 30.26 (+3.00%)
COO : 294.63 (+0.79%)
JNJ : 138.69 (+1.52%)
NVS : 94.64 (+1.43%)
Alkermes Focuses on Pipeline, Depends on Partners for Funds

Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.

JNJ : 138.69 (+1.52%)
LLY : 131.45 (+1.22%)
ALKS : 33.70 (+0.96%)
BIIB : 226.06 (+2.63%)
Asian shares gain as Fed says it will hold off on rate hikes

BANGKOK (AP) — Shares in Asia were mostly higher on Thursday after the Federal Reserve said it has ruled out interest rate increases for this year.

MSFT : 117.98 (+0.27%)
GIS : 51.45 (+0.70%)
GOOGL : 1,197.00 (-0.03%)
CI : 162.26 (-0.92%)
JNJ : 138.69 (+1.52%)
FDX : 174.15 (+1.21%)
UNH : 245.36 (-0.61%)
KEY : 15.22 (+1.47%)
FedEx, Johnson and Johnson slump while General Mills rises

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Wednesday:

SCS : 14.99 (+1.01%)
JNJ : 138.69 (+1.52%)
AIR : 32.53 (+0.53%)
FDX : 174.15 (+1.21%)
SMAR : 41.80 (+1.41%)
VIA : 33.87 (+3.58%)
Markets Right Now: Fed news sends bond yields sharply lower

NEW YORK (AP) — The latest on developments in financial markets (all times local):

JNJ : 138.69 (+1.52%)
VIA : 33.87 (+3.58%)
AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

JNJ : 138.69 (+1.52%)
ABBV : 81.05 (+1.94%)
TEVA : 15.72 (-1.13%)
RHHBY : 34.2700 (+1.30%)

Van Meerten Stock Picks

Trilogy Metals - Pick of the Day
My Stock Pick of the Day belongs metal mining company Trilogy Metals(TMQ).
TMQ +0.03
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar